<DOC>
	<DOCNO>NCT02800824</DOCNO>
	<brief_summary>To evaluate bioequivalence Test Product Budesonide rectal aerosol foam Reference Product Uceris® rectal aerosol foam single-dose healthy subject</brief_summary>
	<brief_title>Bioequivalence Study Budesonide Rectal Aerosol Foam Uceris® Rectal Aerosol Foam</brief_title>
	<detailed_description />
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Healthy , nonsmoking , male female subject , 18 year age . 2 . No clinically significant finding vital sign measurement 12lead electrocardiogram ( ECG ) abnormal laboratory value . 3 . Have significant disease . 4 . Willing use acceptable , effective method contraception . 5 . Informed nature study agree able read , review sign consent document . 6 . Have clinically significant finding physical examination . 1 . Known history presence clinically significant neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , genitourinary , psychiatric , cardiovascular disease condition , opinion Investigator , would jeopardize safety subject impact validity study result 2 . Known history presence hypersensitivity idiosyncratic reaction budesonide , component drug product , drug substance similar activity sodium phosphate 3 . History presence diabetes mellitus , glaucoma cataract , hypertension , osteoporosis 4 . History drug alcohol addiction require treatment . 5 . History malabsorption within last year . 6 . Presence hepatic renal dysfunction . 7 . Presence medical condition require regular medication ( prescription and/or overthecounter ) systemic absorption . 8 . Positive test result HIV , Hepatitis B surface antigen , Hepatitis C antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>